{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:39:01Z","timestamp":1790573941357,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031288","name":"F2G","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U19AI166798-02"],"award-info":[{"award-number":["5U19AI166798-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.idc.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:30:57Z","timestamp":1734766257000},"page":"183-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Coccidioidomycosis"],"prefix":"10.1016","volume":"39","author":[{"given":"Fariba M.","family":"Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Ampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2024.11.012_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3181\/00379727-29-6159","article-title":"Isolation of coccidioides immitis(stiles) from the soil","volume":"29","author":"Stewart","year":"1932","journal-title":"Proc Soc Exp Biol Med"},{"issue":"Supplement_1","key":"10.1016\/j.idc.2024.11.012_bib2","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/mmy\/myy039","article-title":"The endozoan, small-mammal reservoir hypothesis and the life cycle of coccidioides species","volume":"57","author":"Taylor","year":"2019","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15572536.2003.11833250","article-title":"Molecular and phenotypic description of coccidioides posadasii sp. nov., previously recognized as the non-California population of coccidioides immitis","volume":"94","author":"Fisher","year":"2002","journal-title":"Mycologia"},{"issue":"Supplement_1","key":"10.1016\/j.idc.2024.11.012_bib4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/mmy\/myy051","article-title":"Coccidioides ecology and genomics","volume":"57","author":"Barker","year":"2019","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00550-16","article-title":"Local population structure and patterns of western hemisphere dispersal for coccidioides spp., the fungal cause of valley fever","volume":"7","author":"Engelthaler","year":"2016","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00232-23","article-title":"Was coccidioides a pre-Columbian hitchhiker to southcentral Washington?","volume":"14","author":"Engelthaler","year":"2023","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib7","first-page":"145","article-title":"Investigating the role of animal burrows on the ecology and distribution of coccidioides spp. in Arizona soils","volume":"185","author":"Kollath","year":"2020","journal-title":"Mycopathologia"},{"issue":"4","key":"10.1016\/j.idc.2024.11.012_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/mmy\/myz093","article-title":"The detection of coccidioides from ambient air in Phoenix, Arizona: evidence of uneven distribution and seasonality","volume":"58","author":"Gade","year":"2020","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41598-024-51407-x","article-title":"Understanding the exposure risk of aerosolized coccidioides in a valley fever endemic metropolis","volume":"14","author":"Porter","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib10","doi-asserted-by":"crossref","DOI":"10.1029\/2021GH000504","article-title":"No consistent link between dust storms and valley fever (coccidioidomycosis)","volume":"5","author":"Comrie","year":"2021","journal-title":"Geohealth"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib11","first-page":"527","article-title":"Tempest from Tehachapi takes toll or coccidioides conveyed aloft and Afar","volume":"129","author":"Pappagianis","year":"1978","journal-title":"West J Med"},{"key":"10.1016\/j.idc.2024.11.012_bib12","doi-asserted-by":"crossref","first-page":"170141","DOI":"10.1016\/j.scitotenv.2024.170141","article-title":"A microbial risk assessor\u2019s guide to valley fever (coccidioides spp.): case study and review of risk factors","volume":"917","author":"Kahn","year":"2024","journal-title":"Sci Total Environ"},{"issue":"7","key":"10.1016\/j.idc.2024.11.012_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7107a1","article-title":"Surveillance for coccidioidomycosis, histoplasmosis, and blastomycosis - United States, 2019","volume":"71","author":"Smith","year":"2022","journal-title":"MMWR Surveill Summ"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3201\/eid3005.231624","article-title":"Coccidioidomycosis-related hospital visits, Texas, USA, 2016-2021","volume":"30","author":"Mayfield","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2024.11.012_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciac882","article-title":"The geographic distribution of dimorphic mycoses in the United States for the modern era","volume":"76","author":"Mazi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2024.11.012_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-020-00431-2","article-title":"Re-drawing the maps for endemic mycoses","volume":"185","author":"Ashraf","year":"2020","journal-title":"Mycopathologia"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib17","article-title":"Advocating for coccidioidomycosis to be a reportable disease nationwide in the United States and encouraging disease surveillance across North and South America","volume":"9","author":"Gorris","year":"2023","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab510","article-title":"Coronavirus disease 2019-associated invasive fungal infection","volume":"8","author":"Baddley","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"2\u20133","key":"10.1016\/j.idc.2024.11.012_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11046-022-00629-6","article-title":"Coccidioidomycosis and COVID-19 infection. An analysis from a single medical center within the coccidioidal endemic area","volume":"187","author":"Huff","year":"2022","journal-title":"Mycopathologia"},{"issue":"35","key":"10.1016\/j.idc.2024.11.012_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030361","article-title":"Impact of COVID-19 on diagnosis of primary pulmonary coccidioidomycosis","volume":"101","author":"Ashcherkin","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.idc.2024.11.012_bib21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41558-022-01426-1","article-title":"Over half of known human pathogenic diseases can be aggravated by climate change","volume":"12","author":"Mora","year":"2022","journal-title":"Nat Clim Change"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/cid\/ciac697","article-title":"Climate change and the epidemiology of infectious diseases in the United States","volume":"76","author":"Edelson","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.idc.2024.11.012_bib23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2023.27724","article-title":"Infectious diseases in a changing climate","volume":"331","author":"Phillips","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.idc.2024.11.012_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1029\/2019GH000209","article-title":"Expansion of coccidioidomycosis endemic regions in the United States in response to climate change","volume":"3","author":"Gorris","year":"2019","journal-title":"Geohealth"},{"issue":"6523","key":"10.1016\/j.idc.2024.11.012_bib25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1126\/science.abe8116","article-title":"3rd. Wildfire smoke, a potential infectious agent","volume":"370","author":"Kobziar","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.idc.2024.11.012_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ajim.23218","article-title":"Coccidioidomycosis outbreak among inmate wildland firefighters: California, 2017","volume":"64","author":"Laws","year":"2021","journal-title":"Am J Ind Med"},{"issue":"34","key":"10.1016\/j.idc.2024.11.012_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.15585\/mmwr.mm7134a4","article-title":"Notes from the field: coccidioidomycosis outbreak among wildland firefighters - California, 2021","volume":"71","author":"Donnelly","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib28","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2542-5196(23)00046-3","article-title":"Risk of systemic fungal infections after exposure to wildfires: a population-based, retrospective study in California","volume":"7","author":"Mulliken","year":"2023","journal-title":"Lancet Planet Health"},{"issue":"4","key":"10.1016\/j.idc.2024.11.012_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/EE9.0000000000000254","article-title":"Association between wildfires and coccidioidomycosis incidence in California, 2000-2018: a synthetic control analysis","volume":"7","author":"Phillips","year":"2023","journal-title":"Environ Epidemiol"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib30","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2666-5247(24)00039-9","article-title":"Impact of climate change and natural disasters on fungal infections","volume":"5","author":"Seidel","year":"2024","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4065\/mcp.2010.0423","article-title":"Coccidioidomycosis in African Americans","volume":"86","author":"Ruddy","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.idc.2024.11.012_bib32","doi-asserted-by":"crossref","DOI":"10.3201\/eid2302.160505","article-title":"Risk factors for disseminated coccidioidomycosis, United States","volume":"23","author":"Odio","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"24","key":"10.1016\/j.idc.2024.11.012_bib33","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2000024","article-title":"Disseminated coccidioidomycosis treated with interferon-gamma and dupilumab","volume":"382","author":"Tsai","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib34","article-title":"Genetic and other determinants for the severity of coccidioidomycosis: a clinician's perspective","volume":"9","author":"Galgiani","year":"2023","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"4","key":"10.1016\/j.idc.2024.11.012_bib35","article-title":"The known and unknown \"knowns\" of human susceptibility to coccidioidomycosis","volume":"10","author":"Hsu","year":"2024","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"22","key":"10.1016\/j.idc.2024.11.012_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159491","article-title":"Immunogenetics associated with severe coccidioidomycosis","volume":"7","author":"Hsu","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00597-12","article-title":"Dectin-1 is required for resistance to coccidioidomycosis in mice","volume":"4","author":"Viriyakosol","year":"2013","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib38","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/cid\/ciad619","article-title":"Clinical testing guidance for coccidioidomycosis, histoplasmosis, and blastomycosis in patients with community-acquired pneumonia for primary and urgent care providers","volume":"78","author":"Smith","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2024.11.012_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1205","article-title":"Comparison of a novel rapid lateral flow assay to enzyme immunoassay results for early diagnosis of coccidioidomycosis","volume":"73","author":"Donovan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib40","article-title":"Evaluation of the analytical performance of a lateral flow assay for the detection of anti-coccidioides antibodies in human sera-Argentina","volume":"10","author":"Viale","year":"2024","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/mmy\/myz067","article-title":"Evaluation of a commercially available, point-of-care coccidioides antibody lateral flow assay to aid in rapid diagnosis of coccidioidomycosis in dogs","volume":"58","author":"Schlacks","year":"2020","journal-title":"Med Mycol"},{"issue":"10","key":"10.1016\/j.idc.2024.11.012_bib42","doi-asserted-by":"crossref","first-page":"e0062323","DOI":"10.1128\/jcm.00623-23","article-title":"Investigation of discordant positive sona lateral flow assay results for detection of coccidioides antibodies","volume":"61","author":"Lu","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.idc.2024.11.012_bib43","doi-asserted-by":"crossref","first-page":"e00631","DOI":"10.1128\/jcm.00631-23","article-title":"Development of a rapid lateral flow assay for detection of anti-coccidioidal antibodies","volume":"61","author":"Grill","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2024.11.012_bib44","first-page":"1","article-title":"Two lateral flow assays for detection of anti-coccidioidal antibodies show similar performance to immunodiffusion in dogs with coccidioidomycosis","author":"Grill","year":"2024","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.idc.2024.11.012_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4049\/jimmunol.87.2.218","article-title":"Immunogenicity of spherule-endospore vaccines of coccidioides immitis for mice","volume":"87","author":"Levine","year":"1961","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.idc.2024.11.012_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4049\/jimmunol.94.1.132","article-title":"Immunization of mice to coccidioides immitis: dose, regimen and spherulation stage of killed spherule vaccines","volume":"94","author":"Levine","year":"1965","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1164\/ajrccm\/148.3.656","article-title":"Evaluation of the protective efficacy of the killed coccidioides immitis spherule vaccine in humans. The valley fever vaccine study group","volume":"148","author":"Pappagianis","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"10.1016\/j.idc.2024.11.012_bib48","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1128\/IAI.00633-16","article-title":"A\u00a0coccidioides posadasii cps1 deletion mutant is avirulent and protects mice from lethal infection","volume":"84","author":"Narra","year":"2016","journal-title":"Infect Immun"},{"issue":"23","key":"10.1016\/j.idc.2024.11.012_bib49","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1016\/j.vaccine.2018.04.026","article-title":"Viable spores of coccidioides posadasii deltacps1 are required for vaccination and provide long lasting immunity","volume":"36","author":"Shubitz","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.idc.2024.11.012_bib50","article-title":"Vaccine protection of mice with primary immunodeficiencies against disseminated coccidioidomycosis","volume":"11","author":"Powell","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"47","key":"10.1016\/j.idc.2024.11.012_bib51","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2021.10.029","article-title":"\u0394cps1 vaccine protects dogs against experimentally induced coccidioidomycosis","volume":"39","author":"Shubitz","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.idc.2024.11.012_bib52","article-title":"Vaccines to prevent coccidioidomycosis: a gene-deletion mutant of coccidioides posadasii as a viable candidate for human trials","volume":"8","author":"Galgiani","year":"2022","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"11","key":"10.1016\/j.idc.2024.11.012_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00070-18","article-title":"Glucan-chitin particles enhance th17 response and improve protective efficacy of a multivalent antigen (rcpa1) against pulmonary coccidioides posadasii infection","volume":"86","author":"Hung","year":"2018","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib54","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.4049\/jimmunol.1900793","article-title":"CARD9-associated dectin-1 and dectin-2 are required for protective iof a multivalent vaccine against Coccidioides posadasii infection","volume":"204","author":"Campuzano","year":"2020","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib55","article-title":"A\u00a0recombinant multivalent vaccine (rcpa1) induces protection for c57bl\/6 and hla transgenic mice against pulmonary infection with both species of coccidioides","volume":"12","author":"Campuzano","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib56","doi-asserted-by":"crossref","first-page":"ofae095","DOI":"10.1093\/ofid\/ofae095","article-title":"Challenges to implementing a vaccine for coccidioidomycosis","volume":"11","author":"Barker","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib57","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Global Health"},{"issue":"4","key":"10.1016\/j.idc.2024.11.012_bib58","article-title":"The quest for a vaccine against coccidioidomycosis: a neglected disease of the Americas","volume":"2","author":"Kirkland","year":"2016","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"Supplement_1","key":"10.1016\/j.idc.2024.11.012_bib59","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1093\/mmy\/myy029","article-title":"Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis","volume":"57","author":"Thompson","year":"2019","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jac\/dky501","article-title":"Tolerability of long-term fluconazole therapy","volume":"74","author":"Davis","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib61","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11908-011-0220-x","article-title":"Long-term voriconazole and skin cancer: is there cause for concern?","volume":"13","author":"Clancy","year":"2011","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.idc.2024.11.012_bib64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0009-2797(78)90068-6","article-title":"Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in candida albicans","volume":"21","author":"van den Bossche","year":"1978","journal-title":"Chem Biol Interact"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccm.2009.02.001","article-title":"Overview of antifungal agents","volume":"30","author":"Thompson","year":"2009","journal-title":"Clin Chest Med"},{"issue":"15","key":"10.1016\/j.idc.2024.11.012_bib66","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib67","doi-asserted-by":"crossref","first-page":"880 e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib68","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"12","key":"10.1016\/j.idc.2024.11.012_bib69","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin b for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2024.11.012_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (f901318) against aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2024.11.012_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00434-21","article-title":"In\u00a0vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2024.11.012_bib73","series-title":"Programs and Abstracts of trends in medical mycology (TIMM)","article-title":"Olorofim treatment of mould IFD in patients with limited or no treatment options: results from a Phase 2b open-label study","author":"Johan Maertens","year":"2023"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01715-18","article-title":"Apx001 and other gwt1 inhibitor prodrugs are effective in experimental coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2024.11.012_bib76","first-page":"705","volume":"43","author":"Glenn","year":"2005","journal-title":"Coccidioidomycosis in hematopoietic stem cell transplant recipients. Medical mycology"},{"issue":"11","key":"10.1016\/j.idc.2024.11.012_bib77","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/cid\/cit114","article-title":"Pediatric coccidioidomycosis in central California: a retrospective case series","volume":"56","author":"McCarty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2024.11.012_bib78","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/cid\/cit113","article-title":"Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series","volume":"56","author":"Levy","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MD.0b013e3181f378a8","article-title":"Coccidioidal meningitis: clinical presentation and management in the fluconazole era","volume":"89","author":"Mathisen","year":"2010","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib80","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.idc.2021.03.010","article-title":"3rd. Coccidioidomycosis","volume":"35","author":"Bays","year":"2021","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib82","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3201\/eid2006.131842","article-title":"Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis","volume":"20","author":"Blair","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2024.11.012_bib83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/595687","article-title":"Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis","volume":"48","author":"Ampel","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2024.11.012_bib84","doi-asserted-by":"crossref","first-page":"e3814","DOI":"10.1093\/cid\/ciaa1154","article-title":"Natural history of disseminated coccidioidomycosis: examination of the veterans affairs-armed forces database","volume":"73","author":"Bays","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib85","first-page":"377","article-title":"Coccidioidomycosis in compromised hosts","volume":"54","author":"Deresinski","year":"1975","journal-title":"Experience at Stanford University Hospital. Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib86","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib87","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/art.39468","article-title":"Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors","volume":"68","author":"Salt","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.idc.2024.11.012_bib88","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of jak inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib89","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/cid\/ciy620","article-title":"The utility of screening for coccidioidomycosis in recipients of inhibitors of tumor necrosis factor alpha","volume":"68","author":"Choi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2024.11.012_bib90","first-page":"3964465","article-title":"Reactivation of coccidioides immitis in a prosthetic knee after initiation of chemotherapy","author":"Ciochetto","year":"2021","journal-title":"Case Rep Hematol"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa167","article-title":"Coccidioidomycosis in patients treated with ruxolitinib","volume":"7","author":"Kusne","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11908-009-0063-x","article-title":"New immunosuppressive agents and risk for invasive fungal infections","volume":"11","author":"Maschmeyer","year":"2009","journal-title":"Curr Infect Dis Rep"},{"issue":"7","key":"10.1016\/j.idc.2024.11.012_bib93","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00296-019-04307-7","article-title":"Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases","volume":"39","author":"Bilal","year":"2019","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.idc.2024.11.012_bib94","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","article-title":"Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Petrelli","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.idc.2024.11.012_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2024.11.012_bib96","article-title":"Infectious complications of CAR T-cell therapy: a longitudinal risk model","volume":"25","author":"Czapka","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2024.11.012_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae133","article-title":"The burden of invasive fungal disease following chimeric antigen receptor t-cell therapy and strategies for prevention","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:51:11Z","timestamp":1762314671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552024000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0891552024000874"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2024.11.012","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coccidioidomycosis","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}